TYSABRI

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug TYSABRI contains one active pharmaceutical ingredient (API):

1	Natalizumab UNII 3JB47N2Q2P - NATALIZUMAB
	Natalizumab is a selective adhesion-molecule inhibitor and binds to the α4-subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils.
	Read more about Natalizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TYSABRI Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AG03	Natalizumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	9505G, 9624M
BR	Câmara de Regulação do Mercado de Medicamentos	538300201159311
CA	Health Products and Food Branch	02286386
EE	Ravimiamet	1250840, 1843882
ES	Centro de información online de medicamentos de la AEMPS	06346001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	056915, 069394
FR	Base de données publique des médicaments	68722564
GB	Medicines & Healthcare Products Regulatory Agency	106264, 396511
HK	Department of Health Drug Office	61519
IL	מִשְׂרַד הַבְּרִיאוּת	6128
IT	Agenzia del Farmaco	037150012, 037150024
JP	医薬品医療機器総合機構	1190402A1028
LT	Valstybinė vaistų kontrolės tarnyba	1031485, 1075654, 1092352
NL	Z-Index G-Standaard, PRK	80934
NZ	Medicines and Medical Devices Safety Authority	12660
PL	Rejestru Produktów Leczniczych	100003952, 100450520
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65148001, W67544001
SG	Health Sciences Authority	14408P
TN	Direction de la Pharmacie et du Médicament	10913041H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699783760014
US	FDA, National Drug Code	64406-008
ZA	Health Products Regulatory Authority	42/30.1/0765